Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01712009 · ClinicalTrials.gov registry record · Phase 2
NOLAN: Naproxen or Loratadine and Neulasta
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT01712009: Completed Phase 2 study, sponsored by Amgen.
NCT01712009 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 600 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (351% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01712009, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
The primary objective of the study is to estimate the difference in bone pain between breast cancer patients receiving chemotherapy and pegfilgrastim and either no prophylactic intervention, prophylactic naproxen, or prophylactic loratadine.
Primary Outcome
Bone pain data were captured as part of standard adverse event (AE) reporting.
Interventions
- DRUG Chemotherapy
- BIOLOGICAL Pegfilgrastim
- DRUG Naproxen
- DRUG Loratadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2012-11-01 |
| Est. Completion | 2015-03-18 |
| Phase | Phase 2 |
What the finished NCT01712009 record still lists
NCT01712009 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (351% higher).
The record links to 0 conditions, and to 4 interventions - of which Chemotherapy is the first listed.
NCT01712009 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01712009 about?
NCT01712009 is a clinical study titled "NOLAN: Naproxen or Loratadine and Neulasta". The primary objective of the study is to estimate the difference in bone pain between breast cancer patients receiving chemotherapy and pegfilgrastim and either no prophylactic intervention, prophylactic naproxen, or prophylactic loratadine.
What is the current status of trial NCT01712009?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2012-11-01. Estimated completion is 2015-03-18.
What interventions are being tested in trial NCT01712009?
The interventions under investigation include: Chemotherapy (DRUG), Pegfilgrastim (BIOLOGICAL), Naproxen (DRUG), Loratadine (DRUG).
Who is sponsoring clinical trial NCT01712009?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01712009's enrollment target sits among peer trials
600 53rd of 2000 higher than 1,945 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI